Search Results 61-70 of 17257 for hba1c

  1. Dietary Interventions in Prediabetes - Clinical Trials

    HbA1c 5.7-6.4 %; BMI 26-40 kg/sq.m. Exclusion Criteria: MRS contraindication; Pregnant women; Liver disease. Participating Mayo Clinic locations. Study statuses ...

  2. Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in Type 1 and Type 2 Diabetes - Mayo Clinic

    HbA1c ³ 10.0%; For female subjects: positive pregnancy test at the time of enrollment or study; History of prior upper abdominal surgery such as adjustable ...

  3. PACTAID App In Adults With Type 1 Diabetes To Help Manage Exercise - Mayo Clinic

    * CGM and insulin pump data available for \> 70% for last 2 weeks. * T1D without atherosclerotic cardiovascular disease * HbA1c ≤10 % * Able to understand ...

  4. Advanced Hybrid Closed Loop (AHCL) System In Type 1 Adult And Pediatric Subjects Utilizing Lyumjev® Insulin Lispro-aabc - Mayo Clinic

    Has a Glycosylated hemoglobin (HbA1c) less than 10% (as processed by Central Lab) at time of screening visit. Note: All HbA1c blood specimens will be sent ...

  5. Hypoglycemia - Symptoms and causes - Mayo Clinic

    Low blood sugar can cause uncomfortable symptoms, such as dizziness and confusion, and can quickly become serious if left untreated.

  6. Impact of Donor Diabetes on DMEK Success and Endothelial Cell Loss (DEKS) - Mayo Clinic

    ... (HbA1c), and skin advanced glycation endproducts (AGE) and oxidation markers, with 1-year graft outcomes (i.e., graft success and ECL) following DMEK in ...

  7. Safety And Efficacy Of EndoBarrier In Subjects With Type 2 Diabetes Who Are Obese - Mayo Clinic

    HbA1c ≥ 7.5% and ≤ 10%; BMI ≥ 30 and ≤ 55. Exclusion Criteria: Diagnosis of type 1 diabetes mellitus or having any history of ketoacidosis; C-peptide < 1.0 ...

  9. The International Diabetes Closed Loop (iDCL) Trial: Protocol 1 - Mayo Clinic

    HbA1c level <10.5% at screening; For females, not currently known to be pregnant; Willingness not to add glucose-lowering agents (such as Pramlintide ...

  10. A Study To Evaluate The Safety And Effectiveness Of Obeticholic Acid Treatment On People With Non-Alcoholic Steatohepatitis With Fibrosis - Mayo Clinic

    HbA1c > 9.5% within 60 days before Day 1. Evidence of other forms of known chronic liver disease including: Positive test result at Screening for hepatitis ...